Accessibility Menu
Medicure logo

Medicure(OTC) MCUJF

Market Cap$9.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-96%
5 Year-4%
1 Year-6%
1 Month+32%
$0.89
+20.43%
+0.15Today
Medicure last closing stock price
MetricPriceDate
Last closeUSD 0.892026-07-31
Medicure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.8%USD 0.812026-07-24
1 month+31.53%USD 0.672026-06-24
3 month+18.31%USD 0.752026-04-24
Year to date+10.95%USD 0.802025-12-31
1 year-5.93%USD 0.942025-07-31
3 year-14.68%USD 1.042023-08-01
5 year-3.87%USD 0.922021-07-30
Since inception-96.3%USD 24.002004-02-17

Medicure Financials at a Glance

Market Cap

$9.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$31.33M

Net Income (TTM)

-CA$6.81M

EPS (TTM)

-$0.47

P/E Ratio

-1.89

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$0.89

Volume

15,270

Open

$0.88

Previous Close

$0.89

Daily Range

$0.88 - $0.94

52-Week Range

$0.67 - $0.97

Estimated Earnings Date

Aug 19, 2026

MCUJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicure

Medicure Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for the cardiovascular market, primarily in Canada and the United States. The company offers a range of products, including AGGRASTAT, ZYPITAMAG, and ReDS, aimed at addressing critical cardiovascular conditions.

Products and Services
  • AGGRASTAT injection for managing acute coronary syndrome
  • ZYPITAMAG for treating primary hyperlipidemia
  • ReDS, a device for measuring lung fluid in heart failure patients
Growth Outlook
  • Recent quarterly revenue reached CAD 7.97 million, showing potential for growth
  • Strong product pipeline targeting cardiovascular health, a growing market
  • Focus on innovative solutions may enhance competitive positioning
Financial Highlights
  • Trailing twelve months revenue of CAD 30.5 million indicates steady demand
  • Gross profit margin improved to 44.3% in the latest quarter
  • Current ratio of 1.04 suggests adequate short-term financial health
Medicure Inc. operates in a specialized sector with a commitment to addressing significant cardiovascular health challenges. The company's flagship products, such as AGGRASTAT, are designed to meet urgent medical needs, while ZYPITAMAG and ReDS expand its therapeutic offerings. Recent financial performance indicates a positive trajectory, with quarterly revenue growth and an improved gross profit margin. The current ratio reflects a stable financial position, allowing for potential investments in research and development. As the cardiovascular market continues to grow, Medicure Inc. is well-positioned to capitalize on emerging opportunities, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Jul 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

Albert D. Friesen, PhD

Website

www.medicure.com

Headquarters

Winnipeg, MB R3T 6C6, CA

MCUJF Financials

Key Financial Metrics (TTM)

Gross Margin

39.68%

Operating Margin

-21.07%

Net Income Margin

-21.74%

Return on Equity

-44.51%

Return on Capital

-49.91%

Return on Assets

-29.13%

Earnings Yield

-52.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.44M

Volume

15.27K

Avg. Volume

694.413

Financials (TTM)

Gross Profit

CA$12.43M

Operating Income

-CA$6.60M

EBITDA

-CA$3.97M

Operating Cash Flow

-CA$3.05M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$3.05M

Cash & ST Invst.

CA$1.55M

Total Debt

CA$805.07K

Medicure Performance Analysis

Medicure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 17,717,0472.2%
20232023-12-31CAD 16,073,357-9.3%
20242024-12-31CAD 15,990,959-0.5%
20252025-12-31CAD 20,650,70929.1%
Medicure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.6%
Q32025-09-3022.3%
Q42025-12-314.6%
Q12026-03-31-6.7%
Medicure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.10N/A
20232023-12-31CAD -0.07N/A
20242024-12-31CAD -0.0711.0%
20252025-12-31CAD -0.49569.5%
Medicure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-14.3%
Q32025-09-30-62.5%
Q42025-12-31-207.7%
Q12026-03-3190.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$7.97M

+45.3%

Gross Profit

CA$3.53M

+24.2%

Gross Margin

44.31%

N/A

Market Cap

$9.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$402.61K

N/A

Employees

23

N/A

Net Income

-CA$407.05K

+41.3%

EBITDA

CA$277.72K

+3571.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$1.55M

-78.6%

Total Debt

CA$805.07K

-8.1%

Accounts Receivable

CA$5.70M

+27.8%

Inventory

CA$3.20M

-18.3%

Long Term Debt

CA$348.90K

-21.8%

Short Term Debt

CA$455.00K

+5.8%

Return on Assets

-29.13%

N/A

Return on Invested Capital

-50.71%

N/A

Free Cash Flow

-CA$1.83M

-378.9%

Operating Cash Flow

-CA$1.83M

-378.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRUFFRed Light Holland Corp.
$0.02+1.36%
UNVCUnivec, Inc.
$0.00+3.13%
CRRTFCrescita Therapeutics, Inc.
$0.56+0.00%
OILFFNextleaf Solutions Ltd.
$0.03+25.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About MCUJF

What is the current price of Medicure?

Medicure is trading at $0.89 per share.

What is the 52-week range for Medicure?

Over the past 52 weeks, Medicure has traded between $0.67 and $0.97.

How much debt does Medicure have?

As of the most recent reporting period, Medicure reported total debt of CA$575.40K.

How much cash does Medicure have on hand?

Medicure reported CA$1.10M in cash and cash equivalents in its most recent financial results.

What is Medicure’s dividend yield?

Medicure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services